The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
 
Dimitrios Makrakis
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Ivan de Kouchkovsky
No Relationships to Disclose
 
Joseph J. Park
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics
 
Rafael Morales-Barrera
Consulting or Advisory Role - AstraZeneca; MSD; Sanofi
Speakers' Bureau - Asofarma; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Johnson & Johnson; Lilly; MSD; Roche/Genentech; Sanofi
 
Michael E. Devitt
Consulting or Advisory Role - Bayer
 
Ariel Ann Nelson
No Relationships to Disclose
 
Benjamin A. Gartrell
No Relationships to Disclose
 
Abhishek Tripathi
Consulting or Advisory Role - Foundation Medicine; Pfizer
Research Funding - Aravive (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); WindMIL (Inst)
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Alejo Rodriguez-Vida
Honoraria - Astellas Oncology; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Oncology; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; MSD; Pfizer; Roche
Research Funding - MSD; Pfizer; Takeda
Travel, Accommodations, Expenses - Astellas Oncology; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Novartis; Pfizer; Roche
 
Sandy Liu
Honoraria - EMD Serono; Exelixis; Merck
Speakers' Bureau - EMD Serono; Exelixis; Merck
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Lucia Andrea Alonso Buznego
Expert Testimony - Roche
 
Jure Murgic
Honoraria - Astellas Pharma; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Sandoz
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Ali Raza Khaki
Stock and Other Ownership Interests - Merck; Sanofi